Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chantal Mathieu

Showing results (11-20 of 625) with videos related to

Pageof 63
Sort By:
Diabetes, Obesity & Metabolism|September 6, 2016
Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomesTim Heise, Chantal Mathieu
Vascular Health and Risk Management|April 2, 2009
Vildagliptin: a new oral treatment for type 2 diabetes mellitusChantal Mathieu, Evy Degrande
Current Opinion in Obstetrics & Gynecology|October 19, 2013
Gestational diabetes: update of screening strategy and diagnostic criteriaKatrien Benhalima, Chantal Mathieu
Reviews in Endocrine & Metabolic Disorders|May 27, 2003
Diabetic ketoacidosisKristina Casteels, Chantal Mathieu
European Endocrinology|April 11, 2018
Sodium-glucose Cotransporter 2 Inhibitors and Ketoacidosis - Clinical Implications in the Treatment of Patients with Type 2 DiabetesKirsten Stinkens, Chantal Mathieu
Lancet (London, England)|July 1, 2011
Arresting type 1 diabetes after diagnosis: GAD is not enoughChantal Mathieu, Pieter Gillard
Expert Opinion on Biological Therapy|March 17, 2011
Immune and cell therapy in type 1 diabetes: too little too late?Pieter Gillard, Chantal Mathieu
Primary Care Diabetes|June 2, 2012
The role of blood glucose monitoring in non-insulin treated type 2 diabetes: what is the evidence?Katrien Benhalima, Chantal Mathieu
Diabetologia|August 8, 2023
Incretins beyond type 2 diabetesChantal Mathieu, Iraj Ahmadzai
Trends in Molecular Medicine|April 3, 2002
The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agentsChantal Mathieu, Luciano Adorini
Pageof 63

Showing results (11-20 of 625) with videos related to

Sort By:
Pageof 63
Diabetes, Obesity & Metabolism|September 6, 2016
Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomesTim Heise, Chantal Mathieu
Vascular Health and Risk Management|April 2, 2009
Vildagliptin: a new oral treatment for type 2 diabetes mellitusChantal Mathieu, Evy Degrande
Current Opinion in Obstetrics & Gynecology|October 19, 2013
Gestational diabetes: update of screening strategy and diagnostic criteriaKatrien Benhalima, Chantal Mathieu
Reviews in Endocrine & Metabolic Disorders|May 27, 2003
Diabetic ketoacidosisKristina Casteels, Chantal Mathieu
European Endocrinology|April 11, 2018
Sodium-glucose Cotransporter 2 Inhibitors and Ketoacidosis - Clinical Implications in the Treatment of Patients with Type 2 DiabetesKirsten Stinkens, Chantal Mathieu
Lancet (London, England)|July 1, 2011
Arresting type 1 diabetes after diagnosis: GAD is not enoughChantal Mathieu, Pieter Gillard
Expert Opinion on Biological Therapy|March 17, 2011
Immune and cell therapy in type 1 diabetes: too little too late?Pieter Gillard, Chantal Mathieu
Primary Care Diabetes|June 2, 2012
The role of blood glucose monitoring in non-insulin treated type 2 diabetes: what is the evidence?Katrien Benhalima, Chantal Mathieu
Diabetologia|August 8, 2023
Incretins beyond type 2 diabetesChantal Mathieu, Iraj Ahmadzai
Trends in Molecular Medicine|April 3, 2002
The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agentsChantal Mathieu, Luciano Adorini
Pageof 63